Remove 2007 Remove Licensing Remove Pharmaceuticals
article thumbnail

2025 Merkin Prize in Biomedical Technology awarded to pioneers of CAR T-cell therapy

Broad Institute

In 2007, Sadelain and Rivire treated their first patient with leukemia, and in 2009, published details on how they manufactured personalized CAR T cells to treat patients with aggressive leukemia. After their clinical results, their technology was licensed to Juno Therapeutics (later acquired by Bristol Myers Squibb.)

article thumbnail

Gepirone

New Drug Approvals

2] Gepirone was synthesized by Bristol-Myers Squibb in 1986 and was developed and marketed by Fabre-Kramer Pharmaceuticals. [4] 5] History Gepirone was developed by Bristol-Myers Squibb in 1986, [5] but was out-licensed to Fabre-Kramer in 1993. 1] It is taken orally. [1] 1] It is taken orally. [1] 5] SYN Synthesis Ormaza, V.

FDA
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Inavolisib

New Drug Approvals

1, 2007, 41-44) (2.30 “An Overview of Bioactive 1,3-Oxazole-Containing Alkaloids from Marine Organisms” Pharmaceuticals. “International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 84” WHO Drug Information. mmol) in methanol (5.0 PMID 34127844. MDPI AG: 1274. 75 (32).

FDA
article thumbnail

Landiolol

New Drug Approvals

0004]The synthesis of Landiolol 1 is disclosed in US 5013734 , JP 3302647 , CN 100506814 , JP 2539734 and Chemical & Pharmaceutical Bulletin 1992, 40 (6) 1462-1469. “Development of a highly cardioselective ultra short-acting beta-blocker, ONO-1101” Chemical & Pharmaceutical Bulletin. June 1992). 40 (6): 14629.

FDA
article thumbnail

Seladelpar

New Drug Approvals

1] [2] [3] The compound was licensed from Janssen Pharmaceutica NV. [4] 2007 Jul 15;17(14):3855-9. Epub 2007 May 10. 2007.05.007 Drug Discovery, Johnson and Johnson Pharmaceutical Research and Development, LLC, 8 Clarke Drive, Cranbury, NJ 08512, USA Scheme 1. Seladelpar cas 851528-79-5 C 21 H 23 F 3 O 5 S, 444.47

FDA
article thumbnail

Acoltremon

New Drug Approvals

“Menthol derivative WS-12 selectively activates transient receptor potential melastatin-8 (TRPM8) ion channels” Pakistan Journal of Pharmaceutical Sciences. 2007 Mar;41(3):285-94. . ^ Ma S, Gisselmann G, Vogt-Eisele AK, Doerner JF, Hatt H (October 2008). 21 (4): 370–378. PMID 18930858. 284 (7): 4102–4111. Beck B, et al.

FDA
article thumbnail

Janssen Announces Novel Mechanism of Action that Shows Promise Against Dengue in Data Published in Nature

The Pharma Data

The Janssen dengue compound discovery program started in 2007. licensed the compound series in 2015, and is continuing to advance the compound into clinical development. 1] This research builds on Johnson & Johnson’s work to advance science against emerging and entrenched global public health threats. Janssen Pharmaceutica, N.V.